Herantis Pharma Oyj (HRPMF) Research

Herantis Pharma Oyj, a biotechnology enterprise, specializes in creating disease-modifying therapies for Parkinson's disease (PD) that harness Cerebral Dopamine Neurotrophic Factor (CDNF). Central to its developmental efforts is HER-096, a sophisticated, compact, synthetic chemical peptidomimetic originating from the active parent molecule. This preclinical xCDNF candidate is currently being investigated for its therapeutic promise in PD and other neurodegenerative conditions. Additionally, the firm is advancing recombinant human Cerebral Dopamine Neurotrophic Factor (rhCDNF), a biological protein that is presently undergoing Phase I clinical evaluation in individuals afflicted with Parkinson's. Founded in 2008, Herantis Pharma Oyj maintains its corporate headquarters in Espoo, Finland.

Market snapshot

Symbol
HRPMF
Price
$3.51
Day change
0.00%
Market cap
$49.7M
P/E ratio
-6.82x
52-week range
3.51-3.51
Sector
Healthcare
Industry
Biotechnology

Peer companies

  • Biostage, Inc. (BSTG)
  • Small Pharma Inc. (DMTTF)
  • Elegance Optical International Holdings Limited (EEOIF)
  • Goodness Growth Holdings, Inc. (GDNSF)
  • Karolinska Development AB (publ) (KDEVF)
  • Mindset Pharma Inc. (MSSTF)
  • Abliva AB (publ) (NEVPF)
  • Oncopeptides AB (publ) (ONPPF)

Open Herantis Pharma Oyj (HRPMF) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.